Document is current
Any future updates will be listed below
-
Authors
McDiarmid, Troy A. https://orcid.org/0000-0002-4893-9733
Taylor, Megan L. https://orcid.org/0009-0002-2511-1498
Chen, Wei https://orcid.org/0000-0002-5255-4166
Chardon, Florence M.
Choi, Junhong https://orcid.org/0000-0001-9291-5977
Liao, Hanna
Li, Xiaoyi
Kim, Haedong https://orcid.org/0000-0003-3589-0042
Lalanne, Jean-Benoît
Li, Tony
Nathans, Jenny F. https://orcid.org/0000-0002-0276-734X
Martin, Beth K. https://orcid.org/0000-0002-9661-014X
Knuth, Jordan https://orcid.org/0009-0007-0176-7093
Coradini, Alessandro L. V.
Gray, Jesse M.
Pinglay, Sudarshan
Shendure, Jay https://orcid.org/0000-0002-1516-1865
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (R01HG010632)
- License Information
-
More Information
Article History
Received: 16 September 2024
Accepted: 7 October 2025
First Online: 11 November 2025
Competing interests
: J.S. is a scientific advisory board member, consultant and/or cofounder of Cajal Neuroscience, Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Phase Genomics, Adaptive Biotechnologies, Scale Biosciences, Sixth Street Capital, Prime Medicine, Somite Therapeutics and Pacific Biosciences. All other authors declare no competing interests.
